| ABSTRACT Objective:To evaluate the efficacy, safety and related factors of vancomycin, teicoplanin and linezolid in the treatment of MRSA. Methods: Screening of a top three hospital from August 2016 to January 2017, these patients with MRSA infectionin who treated with the vancomycin, teicoplanin and linezolid were chosen. The age, sex, location of infection, etiological examination, medication, adverse drug reactions in three groups were analyzed and the curative effect were compared. Results:A total of 260 patients were included, infected people mainly in the elderly, the main parts of the infection in the lungs, abdominal cavity, intracranial, skin and soft tissue and blood. The clinical effective rates of vancomycin group (100 cases), teicoplanin group (80 cases) and linezolid group (80 cases) were 68.00%, 70.00% and 73.75% respectively, there were no statistical difference (P＞0.05). The incidences of adverse drug reactions were 23.00%, 7.50% and 30.00% respectively. There were a statistically significant difference between the tecolanine group compared with the vancomycin group and the linezolid group (P<0.01). There were 16 cases of renal damage in vancomycin group and 16 cases of platelet reduction in linezolid group. Conclusion:The low efficiency of the three groups of drugs might be related to the choice of medication at the infected site, less therapeutic drug monitoring, adverse reactions, inadequate dose loading of the first dose and co infection, and clinical treatment should be emphasized. |
